311 related articles for article (PubMed ID: 33421213)
1. Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19).
Santeusanio AD; Menon MC; Liu C; Bhansali A; Patel N; Mahir F; Rana M; Tedla F; Mahamid A; Fenig Y; Zendel A; Delaney V; De Boccardo G; Farouk SS; Sehgal V; Khaim R; Jacobs SE; Dunn D; Sullivan T; Taimur S; Baneman E; Florman S; Shapiro R
Clin Transplant; 2021 Apr; 35(4):e14221. PubMed ID: 33421213
[TBL] [Abstract][Full Text] [Related]
2. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center.
Lubetzky M; Aull MJ; Craig-Schapiro R; Lee JR; Marku-Podvorica J; Salinas T; Gingras L; Lee JB; Sultan S; Kodiyanplakkal RP; Hartono C; Saal S; Muthukumar T; Kapur S; Suthanthiran M; Dadhania DM
Nephrol Dial Transplant; 2020 Jul; 35(7):1250-1261. PubMed ID: 32678882
[TBL] [Abstract][Full Text] [Related]
3. Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry.
López-Oliva MO; Pérez-Flores I; Molina M; José Aladrén M; Trujillo H; Redondo-Pachón D; López V; Facundo C; Villanego F; Rodríguez M; Carmen Ruiz M; Antón P; Rivas-Oural A; Cabello S; Portolés J; de la Vara L; Tabernero G; Valero R; Galeano C; Moral E; Ventura A; Coca A; Ángel Muñoz M; Hernández-Gallego R; Shabaka A; Ledesma G; Bouarich H; Ángeles Rodríguez M; Pérez Tamajón L; Cruzado L; Emilio Sánchez J; Jiménez C
Nefrologia (Engl Ed); 2023; 43(4):442-451. PubMed ID: 37661514
[TBL] [Abstract][Full Text] [Related]
4. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.
Cristelli MP; Tedesco-Silva H; Medina-Pestana JO; Franco MF
Transpl Infect Dis; 2013 Aug; 15(4):369-78. PubMed ID: 23701592
[TBL] [Abstract][Full Text] [Related]
5. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?
Rodriguez-Cubillo B; de la Higuera MAM; Lucena R; Franci EV; Hurtado M; Romero NC; Moreno AR; Valencia D; Velo M; Fornie IS; Sanchez-Fructuoso AI
Am J Transplant; 2020 Nov; 20(11):3173-3181. PubMed ID: 32529737
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression reduction in kidney transplant recipients during bacterial infection-A retrospective study.
Yahav D; Sulimani O; Green H; Margalit I; Ben-Zvi H; Mor E; Rozen-Zvi B
Clin Transplant; 2019 Oct; 33(10):e13707. PubMed ID: 31494965
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium.
Cravedi P; Mothi SS; Azzi Y; Haverly M; Farouk SS; Pérez-Sáez MJ; Redondo-Pachón MD; Murphy B; Florman S; Cyrino LG; Grafals M; Venkataraman S; Cheng XS; Wang AX; Zaza G; Ranghino A; Furian L; Manrique J; Maggiore U; Gandolfini I; Agrawal N; Patel H; Akalin E; Riella LV
Am J Transplant; 2020 Nov; 20(11):3140-3148. PubMed ID: 32649791
[TBL] [Abstract][Full Text] [Related]
9. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.
Jung HY; Lee S; Jeon Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
J Korean Med Sci; 2020 Jun; 35(24):e185. PubMed ID: 32567256
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid.
Morales JM; Andrés A; Morales E; Herrero JC; Cubas A; Praga M; Hernández E; Ortuño T; Dominguez-Gil B; Carreño A; Delgado M; Manzanares C
Transplant Proc; 1999 Nov; 31(7A):75S-77S. PubMed ID: 10576051
[No Abstract] [Full Text] [Related]
13. Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience.
Lum E; Bunnapradist S; Multani A; Beaird OE; Carlson M; Gaynor P; Kotton C; Abdalla B; Danovitch G; Kendrick E; Nieves-Borrero K; Pham PT; Yabu J; Schaenman J
Transplant Proc; 2020 Nov; 52(9):2654-2658. PubMed ID: 33041077
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
Triemer HL; Pearson TC; Odom KL; Larsen CP
Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
[TBL] [Abstract][Full Text] [Related]
15. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
16. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of COVID-19 disease in immunosuppressed renal transplant patients.
Dheir H; Sipahi S; Yaylacı S; Çetin ES; Genç AB; Fırat N; Köroğlu M; Muratdağı G; Tomak Y; Özmen K; Ateş ÖF; Karabay O
Turk J Med Sci; 2021 Apr; 51(2):428-434. PubMed ID: 33185367
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.
Colmenero J; Rodríguez-Perálvarez M; Salcedo M; Arias-Milla A; Muñoz-Serrano A; Graus J; Nuño J; Gastaca M; Bustamante-Schneider J; Cachero A; Lladó L; Caballero A; Fernández-Yunquera A; Loinaz C; Fernández I; Fondevila C; Navasa M; Iñarrairaegui M; Castells L; Pascual S; Ramírez P; Vinaixa C; González-Dieguez ML; González-Grande R; Hierro L; Nogueras F; Otero A; Álamo JM; Blanco-Fernández G; Fábrega E; García-Pajares F; Montero JL; Tomé S; De la Rosa G; Pons JA
J Hepatol; 2021 Jan; 74(1):148-155. PubMed ID: 32750442
[TBL] [Abstract][Full Text] [Related]
20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
